Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 256

1.

Preliminary Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL).

Lampson BL, Tyekucheva S, Crombie JL, Kim AI, Merryman RW, Lowney J, Montegaard J, Patterson V, Jacobson CA, Jacobsen ED, LaCasce AS, Arnason JE, Armand P, Fisher DC, Brown JR, Davids MS.

Blood. 2019 Nov 13;134(Supplement_1):32. doi: 10.1182/blood-2019-127506.

PMID:
31723987
2.

Optimizing selective stimulation of peripheral nerves with arrays of coils or surface electrodes using a linear peripheral nerve stimulation metric.

Davids M, Guerin B, Klein V, Schmelz M, Schad LR, Wald LL.

J Neural Eng. 2019 Oct 30. doi: 10.1088/1741-2552/ab52bd. [Epub ahead of print]

PMID:
31665707
3.

Salivary creatinine as a diagnostic tool for evaluating patients with chronic kidney disease.

Temilola DO, Bezuidenhout K, Erasmus RT, Stephen L, Davids MR, Holmes H.

BMC Nephrol. 2019 Oct 29;20(1):387. doi: 10.1186/s12882-019-1546-0.

4.

Dietary fibre enrichment of supplemental feed modulates the development of the intestinal tract in suckling piglets.

Van Hees HMJ, Davids M, Maes D, Millet S, Possemiers S, den Hartog LA, van Kempen TATG, Janssens GPJ.

J Anim Sci Biotechnol. 2019 Oct 8;10:83. doi: 10.1186/s40104-019-0386-x. eCollection 2019.

5.

Urine lipoarabinomannan (LAM) and antimicrobial usage in seriously-ill HIV-infected patients with sputum smear-negative pulmonary tuberculosis.

Mthiyane T, Peter J, Allen J, Connolly C, Davids M, Rustomjee R, Holtz TH, Malinga L, Dheda K.

J Thorac Dis. 2019 Aug;11(8):3505-3514. doi: 10.21037/jtd.2019.07.69.

6.

Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies.

Guièze R, Liu VM, Rosebrock D, Jourdain AA, Hernández-Sánchez M, Martinez Zurita A, Sun J, Ten Hacken E, Baranowski K, Thompson PA, Heo JM, Cartun Z, Aygün O, Iorgulescu JB, Zhang W, Notarangelo G, Livitz D, Li S, Davids MS, Biran A, Fernandes SM, Brown JR, Lako A, Ciantra ZB, Lawlor MA, Keskin DB, Udeshi ND, Wierda WG, Livak KJ, Letai AG, Neuberg D, Harper JW, Carr SA, Piccioni F, Ott CJ, Leshchiner I, Johannessen CM, Doench J, Mootha VK, Getz G, Wu CJ.

Cancer Cell. 2019 Oct 14;36(4):369-384.e13. doi: 10.1016/j.ccell.2019.08.005. Epub 2019 Sep 19.

PMID:
31543463
7.

Cerebral and portal vein thrombosis, macrocephaly and atypical absence seizures in Glycosylphosphatidyl inositol deficiency due to a PIGM promoter mutation.

Pode-Shakked B, Heimer G, Vilboux T, Marek-Yagel D, Ben-Zeev B, Davids M, Ferreira CR, Philosoph AM, Veber A, Pode-Shakked N, Kenet G, Soudack M, Hoffmann C, Vernitsky H, Safaniev M, Lodzki M, Lahad A, Shouval DS, Levinkopf D, Weiss B, Barg AA, Daka A, Amariglio N, Malicdan MCV, Gahl WA, Anikster Y.

Mol Genet Metab. 2019 Aug 14. pii: S1096-7192(19)30527-X. doi: 10.1016/j.ymgme.2019.08.003. [Epub ahead of print]

PMID:
31445883
8.

Sleepiness Score-Specific Outcomes of a Novel Tongue Repositioning Procedure for the Treatment of Continuous Positive Airway Pressure-Resistant Obstructive Sleep Apnea.

Hendricks R, Davids M, Khalfey H, Landman HJ, Theron AE, Engela E, Dheda K.

Ann Maxillofac Surg. 2019 Jan-Jun;9(1):28-36. doi: 10.4103/ams.ams_151_18.

9.

Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia.

Staber PB, Herling M, Bellido M, Jacobsen ED, Davids MS, Kadia TM, Shustov A, Tournilhac O, Bachy E, Zaja F, Porkka K, Hoermann G, Simonitsch-Klupp I, Haferlach C, Kubicek S, Mayerhoefer ME, Hopfinger G, Jaeger U, Dearden C.

Blood. 2019 Oct 3;134(14):1132-1143. doi: 10.1182/blood.2019000402. Epub 2019 Jul 10. Review.

PMID:
31292114
10.

Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report.

Kim HT, Ahn KW, Hu ZH, Davids MS, Volpe VO, Antin JH, Sorror ML, Shadman M, Press O, Pidala J, Hogan W, Negrin R, Devine S, Uberti J, Agura E, Nash R, Mehta J, McGuirk J, Forman S, Langston A, Giralt SA, Perales MA, Battiwalla M, Hale GA, Gale RP, Marks DI, Hamadani M, Ganguly S, Bacher U, Lazarus H, Reshef R, Hildebrandt GC, Inamoto Y, Cahn JY, Solh M, Kharfan-Dabaja MA, Ghosh N, Saad A, Aljurf M, Schouten HC, Hill BT, Pawarode A, Kindwall-Keller T, Saba N, Copelan EA, Nathan S, Beitinjaneh A, Savani BN, Cerny J, Grunwald MR, Yared J, Wirk BM, Nishihori T, Chhabra S, Olsson RF, Bashey A, Gergis U, Popat U, Sobecks R, Alyea E, Saber W, Brown JR.

Clin Cancer Res. 2019 Aug 15;25(16):5143-5155. doi: 10.1158/1078-0432.CCR-18-3988. Epub 2019 Jun 28.

PMID:
31253630
11.

Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial.

Davids MS, Brander DM, Kim HT, Tyekucheva S, Bsat J, Savell A, Hellman JM, Bazemore J, Francoeur K, Alencar A, Shune L, Omaira M, Jacobson CA, Armand P, Ng S, Crombie J, LaCasce AS, Arnason J, Hochberg EP, Takvorian RW, Abramson JS, Fisher DC, Brown JR; Blood Cancer Research Partnership of the Leukemia & Lymphoma Society.

Lancet Haematol. 2019 Aug;6(8):e419-e428. doi: 10.1016/S2352-3026(19)30104-8. Epub 2019 Jun 14.

PMID:
31208944
12.

Lysosomal Storage and Albinism Due to Effects of a De Novo CLCN7 Variant on Lysosomal Acidification.

Nicoli ER, Weston MR, Hackbarth M, Becerril A, Larson A, Zein WM, Baker PR 2nd, Burke JD, Dorward H, Davids M, Huang Y, Adams DR, Zerfas PM, Chen D, Markello TC, Toro C, Wood T, Elliott G, Vu M; Undiagnosed Diseases Network, Zheng W, Garrett LJ, Tifft CJ, Gahl WA, Day-Salvatore DL, Mindell JA, Malicdan MCV.

Am J Hum Genet. 2019 Jun 6;104(6):1127-1138. doi: 10.1016/j.ajhg.2019.04.008. Epub 2019 May 30.

PMID:
31155284
13.

IL-4 subverts mycobacterial containment in Mycobacterium tuberculosis-infected human macrophages.

Pooran A, Davids M, Nel A, Shoko A, Blackburn J, Dheda K.

Eur Respir J. 2019 Aug 8;54(2). pii: 1802242. doi: 10.1183/13993003.02242-2018. Print 2019 Aug.

PMID:
31097521
14.

Phase 1 study of lenalidomide, bendamustine, and rituximab in previously untreated patients with chronic lymphocytic leukemia.

Soumerai JD, Davids MS, Werner L, Fisher DC, Armand P, Amrein PC, Neuberg D, Hochberg EP, Brown JR, Abramson JS.

Leuk Lymphoma. 2019 May 10:1-8. doi: 10.1080/10428194.2019.1608533. [Epub ahead of print]

PMID:
31074316
15.

Psoriasiform eruptions secondary to phosphoinositide 3-kinase inhibition.

Dewan AK, Gupta S, Bach DQ, Jadeja S, Granter S, LaCasce A, Joyce R, Davids MS, Huang V, LeBoeuf NR.

JAAD Case Rep. 2019 Apr 20;5(5):401-405. doi: 10.1016/j.jdcr.2018.03.005. eCollection 2019 May. No abstract available.

16.

Venetoclax: R-CHOP rocket booster?

Herbaux C, Davids MS.

Blood. 2019 May 2;133(18):1922-1924. doi: 10.1182/blood-2019-03-901082. No abstract available.

PMID:
31048302
17.

Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables.

Roberts AW, Ma S, Kipps TJ, Coutre SE, Davids MS, Eichhorst B, Hallek M, Byrd JC, Humphrey K, Zhou L, Chyla B, Nielsen J, Potluri J, Kim SY, Verdugo M, Stilgenbauer S, Wierda WG, Seymour JF.

Blood. 2019 Jul 11;134(2):111-122. doi: 10.1182/blood.2018882555. Epub 2019 Apr 25.

18.

Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemia.

Lampson BL, Kim HT, Davids MS, Abramson JS, Freedman AS, Jacobson CA, Armand PA, Joyce RM, Arnason JE, Rassenti LZ, Kipps TJ, Fein J, Fernandes SM, Hanna JR, Fisher DC, Brown JR.

Blood Adv. 2019 Apr 9;3(7):1167-1174. doi: 10.1182/bloodadvances.2018030221.

19.

Quality of life among patients with moderate to advanced chronic kidney disease in Ghana - a single centre study.

Tannor EK, Norman BR, Adusei KK, Sarfo FS, Davids MR, Bedu-Addo G.

BMC Nephrol. 2019 Apr 8;20(1):122. doi: 10.1186/s12882-019-1316-z.

20.

Differential Targeting of c-Maf, Bach-1, and Elmo-1 by microRNA-143 and microRNA-365 Promotes the Intracellular Growth of Mycobacterium tuberculosis in Alternatively IL-4/IL-13 Activated Macrophages.

Tamgue O, Gcanga L, Ozturk M, Whitehead L, Pillay S, Jacobs R, Roy S, Schmeier S, Davids M, Medvedeva YA, Dheda K, Suzuki H, Brombacher F, Guler R.

Front Immunol. 2019 Mar 19;10:421. doi: 10.3389/fimmu.2019.00421. eCollection 2019.

21.

Utility of positron emission tomography-computed tomography in patients with chronic lymphocytic leukemia following B-cell receptor pathway inhibitor therapy.

Mato AR, Wierda WG, Davids MS, Cheson BD, Coutre SE, Choi M, Furman RR, Heffner L, Barr PM, Eradat H, Ford SM, Zhou L, Verdugo M, Humerickhouse RA, Potluri J, Byrd JC.

Haematologica. 2019 Nov;104(11):2258-2264. doi: 10.3324/haematol.2018.207068. Epub 2019 Mar 28.

22.

Spatial Network Mapping of Pulmonary Multidrug-Resistant Tuberculosis Cavities Using RNA Sequencing.

Dheda K, Lenders L, Srivastava S, Magombedze G, Wainwright H, Raj P, Bush SJ, Pollara G, Steyn R, Davids M, Pooran A, Pennel T, Linegar A, McNerney R, Moodley L, Pasipanodya JG, Turner CT, Noursadeghi M, Warren RM, Wakeland E, Gumbo T.

Am J Respir Crit Care Med. 2019 Aug 1;200(3):370-380. doi: 10.1164/rccm.201807-1361OC.

23.

Weight Gain after Fecal Microbiota Transplantation in a Patient with Recurrent Underweight following Clinical Recovery from Anorexia Nervosa.

de Clercq NC, Frissen MN, Davids M, Groen AK, Nieuwdorp M.

Psychother Psychosom. 2019;88(1):58-60. doi: 10.1159/000495044. Epub 2019 Jan 9. No abstract available.

24.

The 'virtual DBS population': five realistic computational models of deep brain stimulation patients for electromagnetic MR safety studies.

Guerin B, Iacono MI, Davids M, Dougherty D, Angelone LM, Wald LL.

Phys Med Biol. 2019 Feb 4;64(3):035021. doi: 10.1088/1361-6560/aafce8.

25.

Hypodipsic-hypernatremia syndrome in an adult with polycythemia: a case report.

Chothia MY, George K, Sheik M, Davids MR.

J Med Case Rep. 2018 Dec 27;12(1):381. doi: 10.1186/s13256-018-1938-y.

26.

Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study.

Davids MS, Kim HT, Nicotra A, Savell A, Francoeur K, Hellman JM, Bazemore J, Miskin HP, Sportelli P, Stampleman L, Maegawa R, Rueter J, Boruchov AM, Arnason JE, Jacobson CA, Jacobsen ED, Fisher DC, Brown JR; Blood Cancer Research Partnership of the Leukemia and Lymphoma Society.

Lancet Haematol. 2019 Jan;6(1):e38-e47. doi: 10.1016/S2352-3026(18)30196-0. Epub 2018 Dec 14.

PMID:
30558987
27.

Sensitivity analysis of neurodynamic and electromagnetic simulation parameters for robust prediction of peripheral nerve stimulation.

Klein V, Davids M, Wald LL, Schad LR, Guérin B.

Phys Med Biol. 2018 Dec 19;64(1):015005. doi: 10.1088/1361-6560/aaf308.

28.

Novel mutations in CLN6 cause late-infantile neuronal ceroid lipofuscinosis without visual impairment in two unrelated patients.

Chin JJ, Behnam B, Davids M, Sharma P, Zein WM, Wang C, Chepa-Lotrea X, Gallantine WB, Toro C, Adams DR, Tifft CJ, Gahl WA, Malicdan MCV.

Mol Genet Metab. 2019 Feb;126(2):188-195. doi: 10.1016/j.ymgme.2018.12.001. Epub 2018 Dec 3.

PMID:
30528883
29.

Awakening the sleeping kidney in a dialysis-dependent patient with fibromuscular dysplasia: A case report and review of literature.

Chothia MY, Davids MR, Bhikoo R.

World J Nephrol. 2018 Nov 24;7(7):143-147. doi: 10.5527/wjn.v7.i7.143.

30.

Venetoclax for chronic lymphocytic leukaemia patients who progress after more than one B-cell receptor pathway inhibitor.

Wierda WG, Byrd JC, Davids MS, Furman RR, Cheson BD, Barr PM, Eradat H, Heffner L, Zhou L, Verdugo M, Potluri J, Choi M.

Br J Haematol. 2019 Jun;185(5):961-966. doi: 10.1111/bjh.15666. Epub 2018 Nov 27. No abstract available.

31.

The Injectable Contraceptive Medroxyprogesterone Acetate Attenuates Mycobacterium tuberculosis-Specific Host Immunity Through the Glucocorticoid Receptor.

Tomasicchio M, Davids M, Pooran A, Theron G, Smith L, Semple L, Meldau R, Hapgood JP, Dheda K.

J Infect Dis. 2019 Apr 8;219(8):1329-1337. doi: 10.1093/infdis/jiy657.

32.

Glycomics in rare diseases: from diagnosis tomechanism.

Davids M, Kane MS, Wolfe LA, Toro C, Tifft CJ, Adams D, Li X, Raihan MA, He M, Gahl WA, Boerkoel CF, Malicdan MCV.

Transl Res. 2019 Apr;206:5-17. doi: 10.1016/j.trsl.2018.10.005. Epub 2018 Oct 23.

PMID:
30423312
33.

Early infantile-onset epileptic encephalopathy 28 due to a homozygous microdeletion involving the WWOX gene in a region of uniparental disomy.

Davids M, Markello T, Wolfe LA, Chepa-Lotrea X, Tifft CJ, Gahl WA, Malicdan MCV.

Hum Mutat. 2019 Jan;40(1):42-47. doi: 10.1002/humu.23675. Epub 2018 Nov 18.

PMID:
30362252
34.

Revised Dose Ramp-Up to Mitigate the Risk of Tumor Lysis Syndrome When Initiating Venetoclax in Patients With Mantle Cell Lymphoma.

Davids MS, von Keudell G, Portell CA, Cohen JB, Fisher DC, Foss F, Roberts AW, Seymour JF, Humerickhouse RA, Tam CS.

J Clin Oncol. 2018 Oct 25:JCO1800359. doi: 10.1200/JCO.18.00359. [Epub ahead of print] No abstract available.

PMID:
30359156
35.

Ofatumumab plus high dose methylprednisolone followed by ofatumumab plus alemtuzumab to achieve maximal cytoreduction prior to allogeneic transplantation for 17p deleted or TP53 mutated chronic lymphocytic leukemia.

Davids MS, Kim HT, Yu L, De Maeyer G, McDonough M, Vartanov AR, Langey R, Fernandes SM, Hellman JM, Francoeur K, Arnason J, Jacobsen ED, LaCasce AS, Fisher DC, Brown JR.

Leuk Lymphoma. 2019 May;60(5):1312-1315. doi: 10.1080/10428194.2018.1519814. Epub 2018 Oct 15.

PMID:
30322319
36.

A new triple threat to CLL.

Lampson BL, Davids MS.

Blood. 2018 Oct 11;132(15):1547-1548. doi: 10.1182/blood-2018-08-870808. No abstract available.

PMID:
30309874
37.
38.

A Recurrent De Novo Heterozygous COG4 Substitution Leads to Saul-Wilson Syndrome, Disrupted Vesicular Trafficking, and Altered Proteoglycan Glycosylation.

Ferreira CR, Xia ZJ, Clément A, Parry DA, Davids M, Taylan F, Sharma P, Turgeon CT, Blanco-Sánchez B, Ng BG, Logan CV, Wolfe LA, Solomon BD, Cho MT, Douglas G, Carvalho DR, Bratke H, Haug MG, Phillips JB, Wegner J, Tiemeyer M, Aoki K; Undiagnosed Diseases Network; Scottish Genome Partnership, Nordgren A, Hammarsjö A, Duker AL, Rohena L, Hove HB, Ek J, Adams D, Tifft CJ, Onyekweli T, Weixel T, Macnamara E, Radtke K, Powis Z, Earl D, Gabriel M, Russi AHS, Brick L, Kozenko M, Tham E, Raymond KM, Phillips JA 3rd, Tiller GE, Wilson WG, Hamid R, Malicdan MCV, Nishimura G, Grigelioniene G, Jackson A, Westerfield M, Bober MB, Gahl WA, Freeze HH.

Am J Hum Genet. 2018 Oct 4;103(4):553-567. doi: 10.1016/j.ajhg.2018.09.003.

39.

The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL.

Flinn IW, Hillmen P, Montillo M, Nagy Z, Illés Á, Etienne G, Delgado J, Kuss BJ, Tam CS, Gasztonyi Z, Offner F, Lunin S, Bosch F, Davids MS, Lamanna N, Jaeger U, Ghia P, Cymbalista F, Portell CA, Skarbnik AP, Cashen AF, Weaver DT, Kelly VM, Turnbull B, Stilgenbauer S.

Blood. 2018 Dec 6;132(23):2446-2455. doi: 10.1182/blood-2018-05-850461. Epub 2018 Oct 4.

40.

An autologous dendritic cell vaccine polarizes a Th-1 response which is tumoricidal to patient-derived breast cancer cells.

Tomasicchio M, Semple L, Esmail A, Meldau R, Randall P, Pooran A, Davids M, Cairncross L, Anderson D, Downs J, Malherbe F, Novitzky N, Panieri E, Oelofse S, Londt R, Naiker T, Dheda K.

Cancer Immunol Immunother. 2019 Jan;68(1):71-83. doi: 10.1007/s00262-018-2238-5. Epub 2018 Oct 3.

41.

Splicing modulation sensitizes chronic lymphocytic leukemia cells to venetoclax by remodeling mitochondrial apoptotic dependencies.

Ten Hacken E, Valentin R, Regis FFD, Sun J, Yin S, Werner L, Deng J, Gruber M, Wong J, Zheng M, Gill AL, Seiler M, Smith P, Thomas M, Buonamici S, Ghia EM, Kim E, Rassenti LZ, Burger JA, Kipps TJ, Meyerson ML, Bachireddy P, Wang L, Reed R, Neuberg D, Carrasco RD, Brooks AN, Letai A, Davids MS, Wu CJ.

JCI Insight. 2018 Oct 4;3(19). pii: 121438. doi: 10.1172/jci.insight.121438.

42.

Prediction of peripheral nerve stimulation thresholds of MRI gradient coils using coupled electromagnetic and neurodynamic simulations.

Davids M, Guérin B, Vom Endt A, Schad LR, Wald LL.

Magn Reson Med. 2019 Jan;81(1):686-701. doi: 10.1002/mrm.27382. Epub 2018 Aug 9.

PMID:
30094874
43.

Evaluation of stacked resonators to enhance the performance of a surface receive-only array for prostate MRI at 3 Tesla.

Chacon-Caldera J, Fischer A, Malzacher M, Vetter Y, Davids M, Flöser M, Stumpf C, Schad LR.

Magn Reson Imaging. 2018 Nov;53:164-172. doi: 10.1016/j.mri.2018.07.010. Epub 2018 Jul 25.

PMID:
30053430
44.

Isavuconazole for the treatment of invasive fungal disease in patients receiving ibrutinib.

Cummins KC, Cheng MP, Kubiak DW, Davids MS, Marty FM, Issa NC.

Leuk Lymphoma. 2019 Feb;60(2):527-530. doi: 10.1080/10428194.2018.1485913. Epub 2018 Jul 24. No abstract available.

PMID:
30037292
45.

The rise of apoptosis: targeting apoptosis in hematologic malignancies.

Valentin R, Grabow S, Davids MS.

Blood. 2018 Sep 20;132(12):1248-1264. doi: 10.1182/blood-2018-02-791350. Epub 2018 Jul 16. Review.

PMID:
30012635
46.

Evaluating the effects of receive-only arrays in specific absorption rate simulations at 3 and 7 T.

Malzacher M, Davids M, Schad LR, Chacon-Caldera J.

Magn Reson Imaging. 2018 Nov;53:7-13. doi: 10.1016/j.mri.2018.06.011. Epub 2018 Jun 26.

PMID:
29958868
47.

Statins enhance efficacy of venetoclax in blood cancers.

Lee JS, Roberts A, Juarez D, Vo TT, Bhatt S, Herzog LO, Mallya S, Bellin RJ, Agarwal SK, Salem AH, Xu T, Jia J, Li L, Hanna JR, Davids MS, Fleischman AG, O'Brien S, Lam LT, Leverson JD, Letai A, Schatz JH, Fruman DA.

Sci Transl Med. 2018 Jun 13;10(445). pii: eaaq1240. doi: 10.1126/scitranslmed.aaq1240.

48.

Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia.

Davids MS, Hallek M, Wierda W, Roberts AW, Stilgenbauer S, Jones JA, Gerecitano JF, Kim SY, Potluri J, Busman T, Best A, Verdugo ME, Cerri E, Desai M, Hillmen P, Seymour JF.

Clin Cancer Res. 2018 Sep 15;24(18):4371-4379. doi: 10.1158/1078-0432.CCR-17-3761. Epub 2018 Jun 12.

49.

Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial.

Stilgenbauer S, Eichhorst B, Schetelig J, Hillmen P, Seymour JF, Coutre S, Jurczak W, Mulligan SP, Schuh A, Assouline S, Wendtner CM, Roberts AW, Davids MS, Bloehdorn J, Munir T, Böttcher S, Zhou L, Salem AH, Desai M, Chyla B, Arzt J, Kim SY, Verdugo M, Gordon G, Hallek M, Wierda WG.

J Clin Oncol. 2018 Jul 1;36(19):1973-1980. doi: 10.1200/JCO.2017.76.6840. Epub 2018 May 1. Erratum in: J Clin Oncol. 2019 Sep 1;37(25):2299.

PMID:
29715056
50.

Review of targeted therapy in chronic lymphocytic leukemia: what a radiologist needs to know about CT interpretation.

Gosangi B, Davids M, Somarouthu B, Alessandrino F, Giardino A, Ramaiya N, Krajewski K.

Cancer Imaging. 2018 Apr 18;18(1):13. doi: 10.1186/s40644-018-0146-8. Review.

Supplemental Content

Loading ...
Support Center